Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efavaleukin alfa - Amgen

Next Previous
X
Search
Drug Profile

Efavaleukin alfa - Amgen

Alternative Names: AMG 592; IL-2 mutein Fc fusion protein - Amgen

Latest Information Update: 28 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Antirheumatics; Cytoprotectives; Immunoglobulin Fc fragments; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus; Ulcerative colitis
  • Phase I/II Graft-versus-host disease
  • No development reported Inflammation
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in United Kingdom (SC)
  • 18 May 2024 Pharmacodynamics data from a phase I trial in Systemic lupus erythematous presented at the Digestive Disease Week 2024 (DDW-2024)
  • 14 Oct 2023 Pooled pharmacodynamics and adverse event data from preclinical and phase I NCT03451422 studies in ulcerative colitis presented at the 31st United European Gastroenterology Week (UEGW-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top